Front Immunol. 2017 Apr 21;8:445. doi: 10.3389/fimmu.2017.00445. eCollection 2017.

Integration of Immune Cell Populations, mRNA-Seq, and CpG Methylation to Better Predict Humoral Immunity to Influenza Vaccination: Dependence of mRNA-Seq/CpG Methylation on Immune Cell Populations.

Frontiers in immunology

Michael T Zimmermann, Richard B Kennedy, Diane E Grill, Ann L Oberg, Krista M Goergen, Inna G Ovsyannikova, Iana H Haralambieva, Gregory A Poland

PMID: 28484452 PMCID: PMC5399034 DOI: 10.3389/fimmu.2017.00445

Abstract

The development of a humoral immune response to influenza vaccines occurs on a multisystems level. Due to the orchestration required for robust immune responses when multiple genes and their regulatory components across multiple cell types are involved, we examined an influenza vaccination cohort using multiple high-throughput technologies. In this study, we sought a more thorough understanding of how immune cell composition and gene expression relate to each other and contribute to interindividual variation in response to influenza vaccination. We first hypothesized that many of the differentially expressed (DE) genes observed after influenza vaccination result from changes in the composition of participants' peripheral blood mononuclear cells (PBMCs), which were assessed using flow cytometry. We demonstrated that DE genes in our study are correlated with changes in PBMC composition. We gathered DE genes from 128 other publically available PBMC-based vaccine studies and identified that an average of 57% correlated with specific cell subset levels in our study (permutation used to control false discovery), suggesting that the associations we have identified are likely general features of PBMC-based transcriptomics. Second, we hypothesized that more robust models of vaccine response could be generated by accounting for the interplay between PBMC composition, gene expression, and gene regulation. We employed machine learning to generate predictive models of B-cell ELISPOT response outcomes and hemagglutination inhibition (HAI) antibody titers. The top HAI and B-cell ELISPOT model achieved an area under the receiver operating curve (AUC) of 0.64 and 0.79, respectively, with linear model coefficients of determination of 0.08 and 0.28. For the B-cell ELISPOT outcomes, CpG methylation had the greatest predictive ability, highlighting potentially novel regulatory features important for immune response. B-cell ELISOT models using only PBMC composition had lower performance (AUC = 0.67), but highlighted well-known mechanisms. Our analysis demonstrated that each of the three data sets (cell composition, mRNA-Seq, and DNA methylation) may provide distinct information for the prediction of humoral immune response outcomes. We believe that these findings are important for the interpretation of current omics-based studies and set the stage for a more thorough understanding of interindividual immune responses to influenza vaccination.

Keywords: cell sorting; data mining; differential expression; immunology; influenza vaccine; machine learning; methylation

References

1. Stat Appl Genet Mol Biol. 2007;6:Article7 - PubMed
2. Immunity. 2015 Dec 15;43(6):1186-98 - PubMed
3. J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9 - PubMed
4. Nat Immunol. 2011 Jul 10;12(8):786-95 - PubMed
5. Vaccine. 2012 Jun 13;30(28):4182-9 - PubMed
6. J Stat Softw. 2010;33(1):1-22 - PubMed
7. Vaccine. 2015 Sep 29;33(40):5294-301 - PubMed
8. Cell. 2014 Apr 10;157(2):499-513 - PubMed
9. Immunology. 2016 Jul;148(3):266-75 - PubMed
10. Proc Biol Sci. 2015 Dec 22;282(1821):20143085 - PubMed
11. Ann N Y Acad Sci. 2000 Jun;908:244-54 - PubMed
12. Bioinformatics. 2009 May 1;25(9):1105-11 - PubMed
13. PLoS One. 2015 Mar 27;10(3):e0122282 - PubMed
14. Heliyon. 2016 May 06;2(5):e00098 - PubMed
15. Hum Mol Genet. 2015 Mar 15;24(6):1791-800 - PubMed
16. Hum Genet. 2012 Sep;131(9):1433-51 - PubMed
17. Nat Methods. 2010 Apr;7(4):287-9 - PubMed
18. Bioinformatics. 2007 Jul 15;23(14):1846-7 - PubMed
19. Vaccine. 2009 Aug 13;27(37):5091-5 - PubMed
20. Semin Immunol. 2013 Apr;25(2):89-103 - PubMed
21. Vaccine. 2003 Mar 7;21(11-12):1180-6 - PubMed
22. J Infect Dis. 2015 Mar 15;211(6):898-905 - PubMed
23. Nat Genet. 2014 Nov;46(11):1173-86 - PubMed
24. J Immunol. 2016 Aug 15;197(4):1460-70 - PubMed
25. Curr Opin Immunol. 2013 Oct;25(5):571-8 - PubMed
26. Stat Appl Genet Mol Biol. 2007;6:Article25 - PubMed
27. Front Immunol. 2016 Nov 02;7:450 - PubMed
28. Bioinformatics. 2010 Mar 15;26(6):841-2 - PubMed
29. PLoS One. 2016 Mar 31;11(3):e0152034 - PubMed
30. Blood. 2011 Mar 31;117(13):3548-58 - PubMed
31. Cell Mol Life Sci. 2017 Apr;74(8):1503-1509 - PubMed
32. Nucleic Acids Res. 2002 Jan 1;30(1):207-10 - PubMed
33. Immunol Rev. 2005 Jun;205:5-6 - PubMed
34. Hum Genet. 2012 Sep;131(9):1403-21 - PubMed
35. Vaccine. 2016 Jul 25;34(34):3993-4002 - PubMed
36. Vaccine. 2014 Feb 7;32(7):881-7 - PubMed
37. Gynecol Endocrinol. 2014 Jan;30(1):16-22 - PubMed
38. Vaccine. 2015 Sep 29;33(40):5262-70 - PubMed
39. Viral Immunol. 2014 May;27(4):174-8 - PubMed
40. Annu Rev Genomics Hum Genet. 2015;16:133-51 - PubMed
41. Hum Vaccin Immunother. 2015;11(4):961-9 - PubMed
42. J Exp Med. 2008 Dec 22;205(13):3119-31 - PubMed
43. J Stat Softw. 2012 Mar;46(11):null - PubMed
44. Cell Rep. 2015 Oct 6;13(1):122-31 - PubMed
45. J Infect Dis. 2011 Apr 1;203(7):921-9 - PubMed

Publication Types

• Journal Article

Grant support

• U01 AI089859/AI/NIAID NIH HHS/United States
• UL1 TR000135/TR/NCATS NIH HHS/United States